A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 01 Oct 2016
At a glance
- Drugs ISIS EIF4ERx (Primary) ; Irinotecan
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 22 Apr 2016 The treatment table has been amended to include one more arm. The dosing cycle of the drug has also been amended.
- 22 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.